Delic Holdings (OTC: DELCF), a Psychedelic Wellness-focused Company, Announces Appointment of John Coleman as Vice President of Business Development

VANCOUVER, BC, March 16, 2021 – Delic Holdings. (“DELIC” or the “Company“) (CSE: DELC) (OTCQB: DELCF), a psychedelic wellness-focused company, is pleased to announce the appointment of John Coleman, PhD, former President of Anandia Labs, as Vice President of Business Development.

Matt Stang commented “We are very fortunate to have John join our team. His pedigree between his corporate and scientific expertise is second to none. Having John join as our VP of Business Development shows our commitment to bringing top tier professionals to our team and having leaders in each pillar of our growing business.”

John has a wide-ranging scientific and business background. In 2013, he co-founded Anandia Labs, a cannabis biotech company focused on genetics and analytics, and helped grow it to approximately 90 staff before Anandia was purchased in 2018 by Aurora Cannabis.

Prior to Anandia, John was the Department Head of the Centre for Drug Research and Development’s (CDRD, now adMare BioInnovations) Project Search and Evaluation Division (2007-2015) where he was responsible for establishing and managing partnerships with academic institutions and identifying projects with therapeutic and commercial potential.

Before CDRD, he held various positions at Inflazyme Pharmaceuticals Ltd. (2000-2007), a Vancouver-based biotechnology company specializing in the development of treatments for respiratory and inflammatory diseases. Prior to Inflazyme, John led the natural products group at Ocean Nutrition Canada (1999-2000) after having completed a postdoctoral fellowship in the Marine Natural Products Chemistry group at the National Research Council in Halifax, Nova Scotia (1998-1999).

John holds a BSc (Honours) from Bishop’s University (1992) and a PhD from the University of British Columbia (1997). His PhD research on naturally-derived anticancer compounds produced the drug candidate HTI-286 that was licensed to Wyeth, where it progressed to Phase II clinical trials.

John commented “I am excited to join the excellent team that Matt and Jackie Stang founded and are building at DELIC to continue unlocking the potential of ketamine and psilocybin, and the potentially addition of other psychedelics, to address psychiatric, behavioral and mental health disorders plaguing our society. DELIC is positioning itself to be a leader in both the educational and scientific sides of the burgeoning psychedelic industry.”

The Company’s Board of Directors have approved the granting of 250,000 incentive stock options to Dr. Coleman at an exercise price of $0.55 as of the closing of business on March 9, 2021. The stock options are exercisable for a period of 3 years in accordance with the terms of the Company’s Incentive Stock Option plan.

About DELIC
DELIC Always Expanding. In All Ways.

DELIC was formed in 2019 to address the growing interest in psychedelic wellness backed by science. DELIC was the ‎first psychedelic umbrella platform and is currently a trusted source for those interested in ‎psychedelic culture, psychedelic clinics, and more. ‎DELIC’s offerings include, Ketamine Infusion Center (under binding acquisition agreement), a limited liability corporation formed under the laws of Arizona and runs two ketamine clinics in Arizona and California, “Reality Sandwich”, a free public education platform providing psychedelic guides, news and ‎culture, “Meet Delic”, the first ever psychedelic wellness summit, and “The Delic”, an e-commerce lifestyle brand. ‎For more information, check out www.deliccorp.com.